Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi will pay Insilico Medicine up to 1.2 billion dollars in milestones plus 21.5 million upfront for AI-discovered drug candidates against up to six…
Insilico Medicine signs strategic research collaboration with Sanofi worth up to $1.2 billion; $21.5M upfront and target-nomination fees, up to six targets via…
Oct 30, 2024: Insilico achieves milestone in Sanofi collaboration - AI lead with first-in-class potential vs an undruggable transcription factor in oncology;…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi entered a multi-year strategic research collaboration with Insilico Medicine (announced November 8, 2022) to deploy Insilico's end-to-end Pharma.AI platform to advance drug candidates against up to six novel targets. Insilico received $21.5M in upfront and target-nomination fees and is eligible for up to $1.2B in research, development and sales milestones plus royalties. On October 30, 2024, Insilico announced the collaboration's first disclosed milestone: an AI-facilitated lead with first-in-class potential against a previously "undruggable" transcription factor target in oncology, generated using Insilico's Chemistry42 engine. Insilico elected to bring that program in-house following a reprioritization by Sanofi, while the companies continue to collaborate on other targets using Insilico's AI discovery tools.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Insilico Medicine Inc. (this deal) | 2022 | $1.2B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Multiple (undisclosed) deals